Xencor Inc (XNCR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Xencor Inc stock (XNCR) is currently trading at $12.40. Xencor Inc PS ratio (Price-to-Sales) is 7.24. Analyst consensus price target for XNCR is $28.42. WallStSmart rates XNCR as Sell.
- XNCR PE ratio analysis and historical PE chart
- XNCR PS ratio (Price-to-Sales) history and trend
- XNCR intrinsic value — DCF, Graham Number, EPV models
- XNCR stock price prediction 2025 2026 2027 2028 2029 2030
- XNCR fair value vs current price
- XNCR insider transactions and insider buying
- Is XNCR undervalued or overvalued?
- Xencor Inc financial analysis — revenue, earnings, cash flow
- XNCR Piotroski F-Score and Altman Z-Score
- XNCR analyst price target and Smart Rating
Xencor Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Xencor Inc (XNCR) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Xencor Inc (XNCR) Key Strengths (2)
112.96% of shares held by major funds and institutions
Trading at 1.40x book value, attractively priced
Supporting Valuation Data
Xencor Inc (XNCR) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -46.50%, a shrinking business
Company is losing money with a negative profit margin
Premium valuation at 7.2x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Xencor Inc (XNCR) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.40) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (7.24) suggest expensive pricing. Growth concerns include Revenue Growth at -46.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -14.10%, Operating Margin at -189.90%, Profit Margin at -73.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -14.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -46.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
XNCR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
XNCR's Price-to-Sales ratio of 7.24x trades at a deep discount to its historical average of 36.77x (10th percentile). The current valuation is 96% below its historical high of 167.95x set in Jul 2015, and 40% above its historical low of 5.17x in May 2025.
WallStSmart Analysis Synopsis
Data-driven financial summary for Xencor Inc (XNCR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Xencor Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 126M with 47% decline year-over-year. The company is currently unprofitable, posting a -73.2% profit margin.
Key Findings
Spending 52% of revenue (65M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 47% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -73.2% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Xencor Inc.
Bottom Line
Xencor Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Xencor Inc(XNCR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.